Simon Tate
Direttore/Membro del Consiglio presso ELIEM THERAPEUTICS, INC.
Patrimonio netto: - $ in data 30/06/2024
Profilo
Simon Nicholas Tate is the founder of Convergence Pharmaceuticals Ltd.
He currently holds the position of Independent Director at Eliem Therapeutics, Inc. since 2019 and Managing Director at Intermediate Capital Group Plc since 2021.
Previously, he served as a Non-Executive Director at Calchan Holdings Ltd.
and Calchan Ltd.
He also held positions at Biogen, Inc. as Vice President & Head-Pain Therapeutic Area and at GlaxoSmithKline, Inc. as VP-Pain & Epilepsy Discovery Performance Unit.
From 2017 to 2021, he worked as a Venture Partner at Bridge Valley Ventures LLP.
Mr. Tate graduated from the University Of Dundee.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
-.--% | 26/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Posizioni attive di Simon Tate
| Società | Posizione | Inizio |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/02/2019 |
| INTERMEDIATE CAPITAL GROUP PLC | Corporate Officer/Principal | 01/01/2021 |
Precedenti posizioni note di Simon Tate
| Società | Posizione | Fine |
|---|---|---|
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Investitore di Private Equity | 01/01/2021 |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Fondatore | 12/04/2018 |
Calchan Ltd.
 Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | - |
| BIOGEN INC. | Corporate Officer/Principal | - |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Formazione di Simon Tate
| University Of Dundee | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| INTERMEDIATE CAPITAL GROUP PLC | Finance |
| Aziende private | 5 |
|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Calchan Holdings Ltd.
 Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Calchan Holdings Ltd. develops novel oral state-dependent calcium channel modulators for chronic pain. The company was founded on February 25, 2011 and is headquartered in London, the United Kingdom. | Health Technology |
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Calchan Ltd.
Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Bridge Valley Ventures LLP
Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Finance |
- Borsa valori
- Insiders
- Simon Tate
